Background Hypertension is a rarely recognized complication of acute lymphoblastic leukemia (ALL). The incidence of hypertension in ALL patients in Indonesia remains unknown, but the most common risk factors are corticosteroid use during induction-phase chemotherapy and renal leukemic infiltration.
H ypertension is one of the adverse effects in patients undergoing chemotherapy, especially those who receive high-dose corticosteroids. Corticosteroid treatment induces apoptosis of leukemic cells, therefore, it is the backbone of induction-phase chemotherapy for acute lymphoblastic leukemia (ALL) and cannot be omitted from the ALL protocol. 1, 2 Other risk factors for hypertension in ALL are hyperleukocytosis and tumor lysis syndrome, as well as renal leukemic infiltration, and sepsis. 3, 4 Electrolyte imbalance and hyperuricemia in tumor lysis syndrome leads to renal injury and hypertension. 5 Renal leukemic infiltration can be detected as renal enlargement by ultrasound examination, and is usually found in newly diagnosed ALL patients. 4, 6 Reported incidences of hypertension in children with ALL or lymphoma varies between centers, ranging from 46% to 67.3%, 6, 7 significantly higher than the incidence of hypertension in the general pediatric population, 1-3%. 8, 9 The incidence of hypertension in pediatric ALL patients in Indonesia is unknown, and hypertension itself and its risk factors are not of great interest nowadays. The purpose of this study was to assess for the incidence of hypertension in pediatric ALL patients, and to assess for associations of hypertension to renal leukemic infiltration, high-dose corticosteroids, and hyperleukocytosis.
Methods
This cross-sectional study was conducted in the Pediatric Wards and Outpatient Clinics of Cipto Mangunkusumo and Dharmais Hospitals from August to December 2012. Subjects were children aged 2 to 18 years with newly diagnosed ALL, or ALL patients who underwent induction-phase chemotherapy. Subjects were also cooperative during blood pressure measurements and their parents agreed to participate in the study. Diagnoses of ALL were established based on microscopic evaluation and immunophenotyping of bone marrow aspirates. We excluded patients who had previously known hypertension or kidney diseases, received anti-hypertensive drugs, consumed corticosteroids prior to ALL diagnosis, or had relapsed ALL. The minimum required sample size was 95, calculated with a formula of single proportion. Subjects (100 total) were recruited by consecutive sampling.
This study was approved by the Ethics Commitee of the Medical Faculty at the University of Indonesia. A complete explanation of the study was given to all participating subjects and parents provided written informed consent. Subjects' baseline characteristics were recorded, including birth date, gender, body weight and height, date of diagnosis, white blood cell (WBC) count at the time of diagnosis, ALL classification, date of chemotherapy onset, corticosteroid dosage, and completed weeks of induction phase.
In an unblinded manner, blood pressure was measured 3 times in the morning or afternoon using a mercury sphygmomanometer (Riester®) and stethoscope (Litmann®). An average of the 3 measurements was recorded for later analysis. Urinary tract ultrasound was performed on subjects with hypertension. Corticosteroid consumption was recorded as the cumulative dose (mg) and total duration (days) from first day of corticosteroid windows to the day of blood pressure measurement. Chi-square and Fisher's exact test with a significance level of P < 0.05 were used to assess for associations between risk factors and hypertension. Statistical analysis was performed using SPSS 20.0 for Windows.
Results
A total of 100 children with ALL fulfilled the study criteria and participated in the study. The numbers of male and female subjects were comparable at a ratio of 1.08:1. Most subjects were aged 2 to 10 years (77%) and had WBC count <50,000/uL (75%). Only 40% of subjects had started induction-phase chemotherapy and received corticosteroids, as shown in Table 1 .
Elevated blood pressure was detected in 6 (10%) of 60 subjects with newly diagnosed ALL and 8 (20%) of 40 subjects who had undergone induction phase chemotherapy. There was 1 subject with hypertensive crisis who presented with seizure and decreased consciousness. He was the only hypertensive subject treated with antihypertensive agents: nifedipine, captopril, and clonidine. Hypertension was detected in 8 of 29 subjects who received dexamethasone, and in no subjects who received prednisone, but the difference was not statistically significant. There was no association between hypertension and corticosteroid administration or age group ( Table 2) .
Renal ultrasound was performed on 12 of 14 subjects with hypertension. The remaining two did not return for an ultrasound examination follow-up visit. Renal enlargement was found in 1/12 subject and there was no association between renal enlargement and chemotherapy status in this study ( Table 3) . Table 1 n=100 48 (48) 77 (77) 23 (23) 60 (60) 29 (29) 11 (11) Hypertension was detected in 3 of 25 subjects with white blood cell (WBC) counts of more than 50,000/uL. Eleven of 75 subjects who had lower WBC counts, had hypertension, but the difference was not statistically significant (P=1.000) ( Table  5) .
We could not evaluate the role of corticosteroid dose on the incidence of hypertension because of the absence of cumulative steroid dose data. Table 4 describes corticosteroid usage based on type, duration, and cumulative dose in subjects with and without hypertension. 
Discussion
Hypertension is a rarely recognized complication of ALL. This is the first study to define the incidence of hypertension and its risk factors in Indonesian children with ALL. Several limitations of this study were its cross-sectional design, which allowed for only onetime rather than daily blood pressure measurements of a cohort design, and its imbalanced proportion of newly diagnosed ALL subjects and ALL subjects who underwent induction-phase chemotherapy (ratio 1.5:1).
The incidence of hypertension in our study was 14%, 10 times higher than the incidence in the general pediatric population (1-3%). [8] [9] [10] [11] [12] This finding was similar to Belgaumi et al. who reported hypertension in 18 (10.7%) of 156 children with ALL, 13 but much lower than the 46% in a study by Attard-Montalto et al. 6 This difference may have been due to the design limitation of our study. Attard-Montalto et al. used a prospective design with daily blood pressure measurements for 28 days of inductionphase chemotherapy, while our study recorded blood pressure measurements only a single time. Therefore, our results do not reflect overall blood pressure patterns in ALL patients before and during chemotherapy. A higher incidence of hypertension was found in the 2 to 10-year-old age group (21%) compared the >10 year-old age group (8%), although the difference was not statistically significant. Similarly, Louis et al. 7 and Olgar et al. 4 reported mean ages of children with hypertension to be 4.2 and 8.9 years, respectively. Those studies did not explain the possible cause of the findings. The incidence of hypertension in subjects who underwent chemotherapy was 2 times higher than in newly diagnosed, untreated ALL subjects. Although statistics showed no significant difference, this finding was clinically significant. Subjects who underwent chemotherapy had 2 times higher risk of developing hypertension than newly diagnosed ALL subjects (OR 2.25; 95%CI 0.72 to 7.07).
Dexamethasone use in the induction phase resulted in 8/29 (27.5%) of subjects with hypertension, while no hypertension was reported in subjects who received prednisone in our study. In contrast, Belgaumi et al. reported 10% and 12.2% incidences of hypertension in subjects who received dexamethasone and prednisone, respectively. 13 This difference may have been due to varying prednisone doses in these studies. Sixty-three of 106 subjects who received prednisone in the Belgaumi et al. study underwent high-risk protocols, therefore, they received a higher prednisone dose (60 mg/m 2 ) than in our study (40 mg/m 2 ). Dexamethasone is more potent than prednisone. The anti-inflammatory effect of 1 mg of dexamethasone is equal to 5-10 mg of prednisone, and an equivalent biological effect is reached in a prednisone (mg)/dexamethasone (mg) ratio [P/D] of 5-10. A P/D ratio of less than 7 results in higher remission rates with dexamethasone, in accordance with increased toxic effects. 2 The P/D ratio in our ALL protocol was 6.6 (40 mg/m 2 /day prednisone in the standard-risk protocol compared to 6 mg/m 2 /day dexamethasone in the high-risk protocol). This ratio contributed to a higher incidence of toxic effects in subjects who received dexamethasone compared to prednisone in our study. Theoretically, a higher cumulative dose of corticosteroids leads to higher incidence of hypertension in ALL patients undergoing chemotherapy, 2 but we did not observe this pattern in our study. The cross-sectional design of our study may contribute to this finding. Hypertension may not have been detected during the single, blood pressure measurement, but may have occurred later.
We used renal enlargement as a parameter for renal involvement in ALL. Renal ultrasound was performed on 12 of 14 patients with hypertension. Renal enlargement was detected in 1/12 of subjects, much lower than the 23.8% incidence of hypertension caused by renal infiltration in a study by Olgar et al. 4 They performed renal ultrasounds on every patient before chemotherapy onset and monitored daily blood Table 5 11 64 0.79 0.20 to 3.12 1.000 3 22 * pressure during the induction phase, therefore, renal infiltration could be optimally detected in their ALL patients.
Hyperuricemia in tumor lysis syndrome may result in renal injury and hypertension in ALL patients with hyperleukocytosis. 5, 14, 15 We did not find a significant association between WBC count and hypertension. The incidence of hypertension was higher in subjects with WBC count <50,000/ uL at the time of diagnosis than in subjects with WBC count >50,000/uL. In contrast, Olgar et al. showed a 28.6% incidence of tumor lysis syndrome in hypertensive subjects, much higher than the 11.5% incidence in normotensive subjects. 4 We found two subjects with hypertension at the time of diagnosis who had hyperleukocytosis with WBC counts of 384,000/uL and 627,000/uL, respectively. The latter subject had an enlarged kidney, which may have indicated hypertension due to renal infiltration. Of 8 patients with hypertension during the induction phase, only 1 subject had hyperleukocytosis with a WBC count of 362,320/uL at the time of diagnosis. It is possible that hypertension in this study was mainly caused by corticosteroid use rather than hyperleukocytosis. Subjects who had high blood pressure at the time of diagnosis may have had the condition previously, while in subjects with hyperleukocytosis, high WBC count may have contributed to high blood pressure.
In conclusion, the incidence of hypertension in pediatric ALL subjects is 14%, ten-times higher than the incidence in the general pediatric population aged 2-18 years (1-3%) . We find no significant associations between hypertension and high-dose corticosteroid use, renal infiltration, or hyperleukocytosis. Hypertension is seen in subjects who receive dexamethasone, but not in subjects who receive prednisone. Routine blood pressure measurements should be done in ALL patients at the first visit, daily during induction-phase chemotherapy, and at every follow-up visit. Prednisone should be the preferred corticosteroid, over dexa-methasone, in induction-phase chemotherapy. We suggest a future cohort study to evaluate renal infiltration and the role of corticosteroid use in pediatric ALL patients with hypertension.
